Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-11-28
1999-10-19
Duffy, Patricia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A01N 3718, A61K 3800
Patent
active
059688947
ABSTRACT:
Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1 and their pentameric subunit B, have been found to be useful in the treatment of mammalian neoplasia, particularly, brain cancer, ovarian cancer, breast cancer and skin cancer. Although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo. Use of a sensitizer, such as sodium butyrate, enhances the efficacy of verotoxins and their subunit B.
REFERENCES:
Costello, P., et al., "Human cerebral endothelium: Isolation and characterization of cells derived from microvessels of non-neoplastic and malignant glial tissue", J. Neuro-Oncology, vol. 8, pp. 231-243 (1990).
Pintus, C., et al., "Endothelial Cell Growth Supplement: a Cell Cloning Factor that Promotes the Growth of Monoclonal Antibody Producing Hybridoma Cells", Journal of Immunological Methods, vol. 61, pp. 195-200 (1983).
Ramotar, K., et al., "Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron", Biochem. J., vol. 272, pp. 805-811 (1990).
Rutka, J.T., et al., "Characterization of Normal Human Brain Cultures", Laboratory Investigation, vol. 55, No. 1, p. 71 (1986).
Sandvig, K., et al., "Toxin-Induced Cell Lysis: Protection by 3-Methyladenine and Cycloheximide", Experimental Cell Research, vol. 200, pp. 253-262 (1992).
Farkas-Himsley, et al: "Bacterial Proteinaceous Products (Bacteriocins) as Cytotoxic Agents of Neoplasia" Cancer Research 36, 3562-3567 (Oct. 1976).
Hill, et al: "Further Studies of the Action of a Partially Purified Bacteriocin against a Murine Fibrosarcoma" Cancer Research, 51, 1359-1365 (Mar. 1, 1991).
Karmali: "Infection by Verocytotoxin-Producing Escherichia coli", Clinical Microbiology Reviews, Jan., 1989 pp. 15-38, vol. 2, No. 1.
Riley, et al: "Hemorrhagic Colitis Associated witha a Rare Escherichia Coli Serotype", The New England Journal of Medicine, vol. 308, No. 12, 681-685 (Mar. 24, 1983).
Lingwood: "Verotoxins and Their Glycolipid Receptors", Advances in Lipid Research, vol. 25, 189-211 (1993).
Van De Kar, et al: "Tumor Necrosis Factor and Interleukin-1 Induce Expression of the Verocytotoxin Receptor Globotriaosylceramide on Human Endothelial Cells: Implications for the Pathogenesis of the Hemolytic Uremic Syndrome", Blood, vol. 80, No. 11, (Dec. 1, 1992) pp. 2755-2764.
Orbig, et al: "Endothelial Heterogeneity inShiga Toxin Receptors and Responses", The Journal of Biological Chemistry, vol. 268, No. 21, Jul. 25, 1993, pp. 15484-15488.
Lingwood: "Verotoxin-Binding in Human Renal Sections", Nephron 1994; 66; 21-28.
Cohen, et al: "Expression of Glycolipid Receptors to Shiga-like Toxin on Human B Lymphocytes: a Mechanism for the failure of long-lived antibody response to dysenteric disease", International Immunology, vol. 2, No. 1, 1990, pp. 1-8.
Gregory, et al: "Identificatioof a Subset of Normal B Cells with a Burkitt's Lymphoma (BL)-like Phenotype" The Journal of Immunology, vol. 139, No. 1, (Jul. 1, 1987) pp. 313-318.
Maloney, et al: "CD19 has a Potential CD77 (Globotriaosyl Ceramide)-binding Site with Sequence Similarity to Verotoxin B-subunits: Implications of Molecular Mimicry for B Cell Adhesion and Enterochemorrhagic Escherichia Coli Pathogenesis", J. Exp. Med. vol. 180 (Jul. 1994) 191-201.
Maloney, et al: "Interaction of Verotoxins with Glycosphingolipids", Trends in Glycoscience and Glycotechnology vol. 5, No. 21 (Jan. 1993) pp. 23-31.
Li, et al: "Accumlation of Globotriaosylceramide in a case of Leiomyosarcoma", Biochemistry J. (1986) vol. 240, 925-927.
Mannori, et al: "Role of Glycolipids in the Metastatic Process: Characteristics of Neutral Glycolipids in Clones with Different Metastatic Potentials Isolated from a Murine Fibrosarcome Cell Line", Int. J. Cancer vol. 45, (1990) pp. 984-988.
Ohyama, et al: "Changes in Clycolipid Expression in Human Testicular Tumor", Int. J. Cancer, vol. 45, (1990) pp. 1040-1044.
Naiki, et al: "Human Erythrocyte P and P.sup.k Blood Group Antigens: Identification as Glycosphingolipids" Biochemical and Biophysical Research Communications, vol. 60, No. 3, 1974--1105-1111.
Pallesen, et al: Distribution of the Burkitt's Lymphoma-associated Antigen (BLA) in Normal Human Tissue and Malignant Lymphoma as Defined by Immunohistological Staining with Monoclonal Antibody 38.13* J Cancer Res Clin Oncol (1987) 113: pp. 67-86.
Kasai, et al: "Tissue Distribution of the P.sup.k Antigen as Determined by a Monoclonal Antibody", Journal of Immunogenetics (1985) vol. 12, pp. 213-220.
Pudymaitis, et al: "Susceptibility to Verotoxin as a Function of the Cell Cycle", Journal of Cellular Physiology, 150: (1992) pp. 632-639.
Lingwood, "Glycolipid Modificationof .alpha.2 Interferon Binding", Biochem, J. vol. 283, (1992) pp. 25-26.
Sandvig, et al: "Retrograde Transport of Endocytossed Shiga Toxin to the Endoplasmic Reticulum", Nature vol. 358, (Aug. 6, 1992) pp. 510-512.
Head, S.C. et al., FEMS Microbiology Letters , 51:211-16, 1988.
Mangeney, M. et al., Cancer Research , 53: 5314-19, 1993.
Farkas-Himsley, deceased Hannah
Geva Ruth
Hill Richard
Kroyanker Leorah
Lingwood Clifford A.
DeConti, Jr. Giulio A.
Duffy Patricia
LandOfFree
Verotoxin pharmaceutical compositions and medical treatments the does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Verotoxin pharmaceutical compositions and medical treatments the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Verotoxin pharmaceutical compositions and medical treatments the will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055402